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SUMMARY 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by 
progressive degradation of motoneurons in the central nervous system (CNS). Astrocytes 
are key regulators for inflammation and neuromodulatory signaling, both of which 
contribute to ALS. The study goal was to ascertain potential temporal changes in astrocyte-
mediated neuromodulatory regulation with transgenic ALS model progression: glutamate, 
GTL-1, GluR1, GluR2, GABA, ChAT activity, VGF, TNF, aspartate, and IGF-1.  We 
examine neuromodulatory changes in data aggregates from 42 peer-reviewed studies 
derived from transgenic ALS mixed cell cultures (neurons + astrocytes).  For each 
corresponding experimental time point, the ratio of transgenic to wild type (WT) was found 
for each compound. ANOVA and a student’s t-test were performed to compare disease 
stages (early, post-onset, and end stage). Glutamate in transgenic SOD1-G93A mixed cell 
cultures does not change over time (p>0.05). GLT-1 levels were found to be decreased 
23% over WT but only at end-stage (p<0.05). Glutamate receptors (GluR1, GluR2) in 
SOD1-G93A were not substantially different from WT, although SOD1-G93A GluR1 
decreased by 21% from post-onset to end-stage (p<0.05). ChAT activity was 
insignificantly decreased.  VGF is decreased throughout ALS (p<0.05).  Aspartate is 
elevated by 25% in SOD1-G93A but only during end-stage (p<0.05). TNF is increased 
by a dramatic 362% (p<0.05).  Furthermore, principal component analysis identified TNF 
as contributing to 55% of the data variance in the first component.  Thus, TNF, which 
modulates astrocyte regulation via multiple pathways, could be a strategic treatment target.  
Overall results suggest changes in neuromodulator levels are subtle in SOD1-G93A ALS 
 xv 
mixed cell cultures.  If excitotoxicity is present as is often presumed, it could be due to 
ALS cells being more sensitive to small changes in neuromodulation.  Hence, seemingly 
unsubstantial or oscillatory changes in neuromodulators could wreak havoc in ALS cells, 
resulting in failed microenvironment homeostasis whereby both hyperexcitability and 
hypoexcitability can coexist.  Future work is needed to examine local, spatiotemporal 















An examination of dynamic, temporal interactions among key players in non-
inflammatory astrocyte homeostasis is necessary to better evaluate ALS etiology and 
therapy. Of course, pathological extracellular increases of glutamate, calcium, and other 
co-factors does lead, or minimally contribute, to co-existing pathology, like oxidative 
stress, inflammation, and excitotoxicity. Such pathological overlap makes detangling the 
multi-factorial ALS etiology all the more difficult. 
Due to the large number of variables, a single all-encompassing in vivo experiment 
is not feasible. Therefore, this study utilizes metadata analysis of aggregated SOD1-G93A 
transgenic ALS mouse experiments to temporally examine relationships in non-
inflammatory astrocyte homeostasis that are potentially key to ALS etiology and 
therapeutic development. The goal of this analysis is to determine temporal trends of non-
inflammatory astrocyte homeostasis over the disease progression of ALS in SOD1-G93A 
mice. We primarily focus on the neuromodulatory regulators and regulation of glutamate, 
calcium, and related cytokines. The current study will address the lack of understanding of 
the temporal changes in astrocyte regulation of glutamate homeostasis. It will also consider 
the in vivo relationships and interactions of regulating molecules in the categories. This 
will be done using meta-analysis of published papers from a database of over 2,000 papers 
on ALS SOD1-G93A mouse model research. This research will help expand the body of 
knowledge on the mechanisms of ALS disease progression, specifically the non-
inflammatory role of the astrocytes. We hope the research will contribute to finding optimal 
times for the different types treatment intervention. 
 xvii 
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CHAPTER 1.       INTRODUCTION 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized 
by the progressive degradation of motoneurons, which results in muscle paralysis, 
respiratory failure, and ultimately death. Its multifactorial nature, population heterogeneity, 
and inherent complexity has made both clinical survival prediction (Pfohl et al., 2018) and 
intervention optimization (Khamankar et al., 2018) extremely difficult. 
Because the multi-factorial nature of ALS is difficult to study in humans, 
experimental mouse models are critical for etiological and treatment elucidation.  The 
superoxide dismutase 1 glycine 93 to alanine (SOD1-G93A) transgenic mouse is currently 
the predominant means of investigating the preclinical pathophysiology of ALS (Pfohl et 
al., 2015) because it of its rich publication history and reproducibility. ALS 
pathophysiology is multi-scalar disturbances that impact numerous processes, including 
inflammation, apoptosis, energetics, excitability, genetic transcription, cellular chemistry, 
oxidative stress, proteomics, and systemic function (Irvin et al., 2015;Kim et al., 2016). 
While ALS is a motoneuron disease, non-neuronal tissues are also affected, including 
astrocytes, glia, and muscle. In fact, inflammation, a process that is predominantly driven 
by non-neural tissue, is the most published etiology examined in SOD1-G93A ALS mice 
(Kim et al., 2016). 
Evidence suggests that non-neuromuscular cells, such as astrocytes, play one of the 
earliest roles in ALS and are being considered as therapeutic targets (Pehar et al., 2017; 
Vargas and Johnson, 2010). Astrocytes are the most abundant subtype of glial cells found 
in the central nervous system (CNS), comprising 20-50% of the brain volume (Rossi and 
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Volterra, 2009). One function of astrocytes is to stabilize the neural microenvironment after 
an injury through the release of cytokines (Rossi and Volterra, 2009). Ideally, the 
inflammatory regulators of astrocytes stimulate the healing process and lay down a 
protective glial scar (Sofroniew, 2009). However, inflammation is also negatively 
implicated across neuropathology, where its consequences can expand the lesion volume 
(Mitchell and Lee, 2008) or perpetuate local dysregulation. For example, in SOD1-G93A 
ALS, there is a dynamic imbalance of cytokines that inappropriately amplifies 
inflammation (Jeyachandran, 2015). Glial fibrillary acid protein (GFAP) levels in SOD1-
G93A mice are almost double those of wild type (WT) mice prior to onset and continue to 
significantly increase with disease progression. Furthermore, ITPR2 gene expression is 
significantly upregulated before and after the induction of induction of inflammation 
(Staats et al., 2016).  
Another key function of astrocytes is to assist in reuptake of neuromodulatory 
agents. It has been proposed that the hyperexcitability of motoneurons is caused by 
overstimulation by the main excitatory neurotransmitter, glutamate, which leads to a large 
influx of calcium (Ca2+) and sodium (Na+) into the cell through glutamate transporter 1 
(GLT-1) (Do-Ha, 2017; Van Den Bosch, 2006). Intracellular Ca2+ levels are further 
increased as Na+ is passed out through the Na+-Ca2+ exchanger (Van Den Bosch, 2006). 
Motoneurons possess little ability to counteract the effects of Ca2+ influx, so 
overstimulation can easily lead to excitotoxicity and cell death (Do-Ha, 2017). Glutamate 
excitotoxicity and impaired intracellular calcium signaling in astrocytes is theorized to 
significantly impact disease progression in ALS and other types of neuropathology 
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(Kawamata, 2014; Staats and Van Den Bosch, 2009). Yet, such neuromodulatory 
regulation mediated by astrocytes is much lesser-studied than inflammation.  
Astrocyte neuromodulatory dysregulation, resulting in failed neuromodulatory 
homeostasis, is thought to contribute significantly to neuronal depolarization, 
hyperexcitability, excitotoxicity, and subsequent neuronal death in ALS (Lin et al., 2013). 
Increased levels of glutamate and reduced levels of excitatory amino acid transporter 2 
(EAAT2) have been found in the CNS of ALS patients, suggesting EAAT2 dysfunction 
and glutamate excitotoxicity is involved in the disease progression (Rothstein et al., 1990; 
Rothstein et al., 1995). It is still unknown as to what causes the glutamate to initially collect 
within the CNS. One possible explanation is that, prior to functional onset of the disease, 
the astrocytes fail to reuptake the extracellular glutamate at the proper homeostatic rate, 
resulting in a slow accumulation. Another explanation is that the motoneurons, or another 
nearby cell, releases glutamate at a significantly higher rate than normal. As part of the 
latter explanation, astrocytes do not compensate for the increased glutamate release and, 
rather, simply continue to reabsorb at a normal rate, resulting in glutamate accumulation 
over time. Many studies (Li et al., 2015) have sought to increase GLT-1 levels in astrocytes 
to increase astrocyte reuptake, albeit unsuccessfully.  
The inhibitory neurotransmitter gamma-Aminobutyric acid (GABA) also has 
therapeutic potential. Mildly reduced expression of GABAergic markers and interneurons 
have been found in some SOD1 mice and ALS patients (Hossaini et al., 2011; Nihei et al., 
1993). GABA transmission can decrease levels of glutamate and protect against excessive 
neuronal damage (Brockington et al., 2013). However, clinical trials of gabapentin, a 
pharmaceutical anti-epileptic drug that modulates GABA, did not extend life span or slow 
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the rate of muscle decline or respiratory function (Diana et al., 2017). Elucidation of 
temporal relationships among glutamate levels, transporter proteins, such as GLT-1 and 
glutamate receptors (GluR), and GABA is needed to determine therapeutic timing and 
efficacy. For example, if glutamate-related treatment must occur well before ALS symptom 
onset to have a functional impact, its clinical treatment value is greatly diminished.  
The adjunctive regulation of intracellular Ca2+ by astrocytes is vital for cell 
signaling. Astrocytes are able to signal neurons by Ca2+ dependent release of glutamate 
(Rossi and Volterra, 2009). Intracellular concentrations of Ca2+ are characteristically 
elevated in response to pathological signaling (Rossi and Volterra, 2009). The glutamate-
mediated excitotoxicity of astrocytes relies on intracellular concentrations of Ca2+ but has 
also been found to be accompanied by the cytokine TNF (Rossi and Volterra, 2009). The 
blockage of the formation of TNF and endoplasmic reticulum (ER) Ca2+ overload have 
a significant negative effect on astrocyte glutamate release (Kawamata and Manfredi, 2010, 
Rossi and Volterra, 2009). Other cytokines, such as VGF nerve growth factor (VGF), 
insulin-like growth factor 1 (IGF-1), aspartate, and choline acetyltransferase (ChAT) can 
also be linked to intracellular calcium levels (Palmieri, 2001; Kandinov, 2013).  
An examination of dynamic, temporal interactions among key players in astrocyte-
mediated neuromodulatory regulation is necessary to better evaluate ALS etiology and 
therapy. Of course, pathological extracellular increases of glutamate, calcium, and other 
co-factors does lead, or minimally contribute, to co-existing pathology, like oxidative 
stress, inflammation, and excitotoxicity. Such pathological overlap makes detangling the 
multi-factorial ALS etiology all the more difficult (Kim et al., 2016). Due to the large 
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number of variables, a single all-encompassing in vivo experiment is not feasible. The goal 
of this study is to determine temporal trends of intrinsic astrocyte-mediated compounds 
that contribute to neuromodulatory regulation over the disease progression of preclinical 
ALS, with the primary focus on regulation of glutamate, GABA, and related compounds.  
Specifically, this metadata analysis is comprised of temporal neuromodulatory data 
compiled from 42 peer-reviewed studies that utilized mixed cultures of astrocytes and 














CHAPTER 2.     METHODS 
 A metadata analysis was performed to construct a macroscopic view of astrocyte-
mediated neuromodulatory regulation over the course of transgenic ALS mouse model 
disease progression. The general method involved (1) mining, selecting and recapturing 
published data from preclinical ALS experiments examining astrocytes; (2) normalizing 
recaptured data to enable aggregation across studies; (3) analyzing aggregate data using 
appropriate statistical methods. 
2.1 Data source identification and inclusion criteria 
 Keywords were used to identify potential data sources in PubMed/Medline. All 
potential data sources were initially searched using key words “Amyotrophic Lateral 
Sclerosis” OR “ALS” AND “transgenic mouse”. Searches were limited to articles 
published in English and with publication dates through June 2018. Primary search articles 
were downloaded into a Filemaker Pro relational database (Mitchell et al., 2015a;Kim et 
al., 2016) and had relevant data recaptured using our lab’s highly accurate biocuration 
process (Mitchell et. al., 2015a). Secondary searches on relevant sub-topics were 
performed within the Filemaker Pro database including all synonyms (see Table 1). We 
specifically utilized the “high-copy” transgenic SOD1-G93A mouse model, which is not 
only more common but also has less implicit outcome heterogeneity (Pfohl et al., 2015). 
Recaptured data included measures of glutamate, GTL-1, GluR1, GluR2, GABA, ChAT 
activity, VGF, TNF, aspartate, and IGF-1, which were identified using searches of figure 
axis labels and figure/table captions. As astrocytic compensation can only be studied in the 
presence of neurons, most data was taken from mixed cultures. Only studies that presented 
quantified data for both transgenic and age-matched wild type control mice were included. 
A total of 42 articles with quantifiable experimental data had data extracted for analysis.   
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2.2 Data normalization and aggregation 
 Recaptured quantified data was used to construct ratios of ALS-representative 
mouse models to wild type (such as, SOD1-G93A / WT) for each included metric at each 
temporal disease stage. Temporal data points were aggregated into three disease stages; 
pre-onset (0-96 days), post-onset (97-116 days), and end stage (117+ days). Disease stages 
were determined by finding the average age of onset (97 days) and survival duration (117+ 
days) for the included mice in the present study. Six of the post-onset glutamate data points 
were empirically extrapolated using standard statistical regression to obtain the necessary 
sample size determined by a standard power analysis. Table 2 illustrates the breakdown of 
the 264 data points (e.g. ratios of transgenic to wild type for each included factor for each 
temporal disease stage).  Aggregation is always an inherent limitation to meta-analysis, 
and this is further discussed in the context of this study in Section 4.9. 
 Not every included journal article expressed the mouse sample size corresponding 
to each of their data points. Thus, each data point (e.g. ratio of transgenic to wild type for 
the included factor measured at a specific temporal disease stage) in the present metadata 
analysis is weighted equally on a per-article basis rather than the corresponding mouse 
sample size comprising the data point. 
 To determine the ALS disease stages, the average onset (97 days) and time of death 
(117 days) was calculated using all included onset and time of death data from the original 
experimental studies (see Supplemental Data Sheet).  Note that these averages are within 
what is expected for high copy SOD1-G93A ALS mice (Pfohl et al., 2015). 
2.3 Statistical analysis 
 The distributions of all data sets were tested with Shapiro-Wilks tests to assure 
sufficient distribution normality for the corresponding statistical tests. To determine 
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statistical significance of differences between disease stages, an ANOVA was performed 
using the Bonferroni correction. To compare protein levels, a Student’s t-test with a 
Bonferroni correction was performed for each disease stage. Error bars on figures 
correspond to the standard deviation. All statistical tests were performed with built-in 
functions in MATLAB (version R2016a). Correlation matrices were constructed to 
visualize the relationships between the analyzed measures. A principal component analysis 
(PCA) was used to evaluate contributions to data variance and visualized reduced data 















CHAPTER 3. RESULTS 
A total of nine astrocyte-mediated neuromodulatory regulators were examined from 42 
peer-reviewed articles. As stated in the Introduction, nearly all of these factors still have 
secondary ties to inflammation. However, the focus of the present study was not on the 
inflammatory roles of astrocytes but rather neuromodulatory regulation of GABA, 
glutamate and calcium related co-factors. Table 2 lists the measures along with the included 
sample size (number of data points). The glutamate excitotoxicity sub-categories included 
glutamate, GLT-1, GluR1, GluR2, and GABA concentrations. The calcium homeostasis 
sub-categories included ChAT activity, VGF, TNF, aspartate, and IGF-1 levels. 
3.1 Glutamate and glutamate transporter proteins 
Glutamate and glutamate transporter levels from mixed cell cultures from SOD1-
G93A ALS mice are compared to wild type.  There was no significant difference in 
glutamate concentrations over disease progression (Figure 1A). Glutamate concentrations 
were also not significantly increased from WT concentrations at any disease stage. GLT-1 
and GluR1 levels decrease over disease progression. At end-stage, GLT-1 levels were 23% 
lower than end-stage WT values (p=0.008) (Figure 1B). GluR1 concentrations at end-stage 
were 21% decreased from pre-onset levels (p=0.035) (Figure 1C). There was no significant 
difference in GluR2 concentrations over disease progression (Figure 1C).  
3.2 GABA 
Next, GABA levels were compared in ALS mice and wild type mice. (Figure 2). 
GABA concentrations showed no significant difference between WT and ALS transgenic 
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values.  Moreover, there was no significant change in GABA over the course of ALS 
disease stage or progression. 
3.3 Other neuromodulatory factors 
Other calcium-related cytokines and neuromodulatory factors were examined over 
temporal SOD1-G93A disease progression (Figure 3).  Choline acetyltransferase (ChAT), 
a transferase enzyme, is responsible for producing the neurotransmitter, acetylcholine 
(ACH).  ChAT activity did not significantly vary over disease progression (Figure 3A).  
The lack of a significant trend in ChAT, which otherwise qualitatively appears to be 
depressed in SOD1-G93A compared to wild type, is confounded by the large variance in 
experimental sample population. Nerve growth factor (VGF) is a secreted protein and 
neuropeptide precursor that may play a role in regulating energy homeostasis, metabolism 
and synaptic plasticity. VGF levels are depressed in SOD1-G93A ALS mixed cultures. 
VGF levels are significantly decreased from WT levels at both pre-onset (p=0.0036) and 
end-stage (p<0.0001), with end-stage being further significantly decreased from pre-onset 
(p=0.0002) (Figure 3B). Tumor necrosis factor alpha (TNF) is a cytokine involved in 
inflammation, apoptosis, and synaptic function. TNF expression in ALS mixed cultures 
significantly increased 362% from WT at end-stage (Figure 3C). Aspartate concentrations 
also significantly increased 25% from WT (Figure 3D) 
3.4 Glutamate, GABA, and cytokine relationships 
A series of cross-correlation matrices were used to examine the correlations between 
various neuromodulatory regulators examined in this study (Figure 4). A cross-correlation 
matrix with correlations was constructed for each disease stage: 0-96 days (pre-onset); 97-
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116 days (post-onset); and 117+ days (end-stage). Highly negatively correlated factors are 
closer to -1, uncorrelated factors are closer to 0, and highly positively correlated factors are 
closer to 1; the illustrated grey scale represents the degree and sign of corresponding 
correlation.  Only factors with a sample size calculated as having sufficient statistical 
power were included in each disease stage matrix. Thus, not every matrix included all 
factors. The pre-onset matrix included the most factors. The notable result from this 
analysis is that ChAT and VGF levels are high positively correlated at pre-onset (p=0.0003) 
(Figure 5).  
A principal component analysis (PCA) was used to determine the individual 
components, which contribute the most to variance in the data (Figure 5). PCA is a type of 
exploratory and dimensionality reduction analysis. It is mathematically defined as an 
orthogonal linear transformation that transforms the data to a new coordinate system such 
that the greatest variance by some projection of the data comes to lie on the first coordinate 
(called the first principal component), the second greatest variance on the second 
coordinate, etc. The biplot displays how much the variables contribute to the variance of 
the first two principal components while also identifying reduced variable clusters (Figure 
5A). The length of each factor’s vector corresponds to the variance explained. Component 
1 accounted for 55% of the variance and was almost completely comprised of TNF 
(Figure 5B). Component 2 accounted for 17% of the variance and was mostly comprised 
of GABA and aspartate (Figure 5C). Interestingly, TNF was nearly orthogonal to GluR1, 
indicating a lack of relationship. 
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Finally, an analysis was performed to determine which normalized cytokine co-
factor levels were significantly different than either glutamate or GABA in mixed cultures 
across each temporal disease stage (Figure 6). VGF levels were significantly decreased 
from glutamate at pre-onset and end-stage (p=0.0331 and p=0.0028) (Figure 6A). TNF 
was significantly increased from glutamate levels at pre-onset (p=0.0018) (Figure 6B). 
GABA levels were not significantly increased from glutamate at any ALS disease stage 
(Figure 6C). ChAT activity was significantly lower than GABA at pre-onset (p=0.0033) 
and end-stage (p=0.009) (Figure 6D). Aspartate concentrations were not significantly 












CHAPTER 4. DISCUSSION 
The metadata analysis results do not paint a picture of widespread, overt glutamate-
mediated excitotoxicity in preclinical ALS as measured in mixed cell cultures.  The key 
neuromodulators, namely glutamate, glutamate receptors and transports, GABA, and 
ChAT, showed no so significant changes in ALS compared to wild type or significant 
changes over the course of ALS disease progression.   GLT-1 and GluR1 were significantly 
decreased at end stage, whereas aspartate was significantly increased at end stage. TNF 
was significantly and drastically increased throughout ALS disease duration, whereas VGF 
was significantly decreased throughout the ALS disease course.  Other than TNF, directly 
measured changes in neuromodulators are modest at best.  Below we discuss what these 
results suggest about the role of astrocyte-mediated neuromodulatory regulation in ALS 
etiology and potential treatments. 
4.1 Evaluating the case for and against ALS excitotoxicity 
Astrocytes play a critical role in reabsorbing excess extracellular glutamate and 
maintaining homeostasis for the motoneurons, which normally prevents excitotoxicity.  
There has been ongoing debate as to the presence or source of possible excitotoxicity (e.g. 
Leroy et. al., 2015, Martínez-Silva et. al., 2018, Rosenblum and Trotti, 2017), especially 
given some animal model experiments suggest ALS motoneurons are hyperexcitable (Jiang 




Previous clinical work illustrated evidence of increased glutamate levels in the CNS 
of ALS patients (Rothstein et al., 1990). Lack of resorption results in glutamate being left 
in the extracellular fluid resulting in continuous over-stimulation of the postsynaptic 
neurons (Rosenblum and Trotti, 2017). However, there was no identified increase in the 
excitatory transmitter, glutamate, in the preclinical ALS model mixed cell cultures 
examined in this study. As improved technology enables further examination, future 
experimental studies should focus on the specific localization of neurotransmitters to 
determine if key neurotransmitter changes are a function of spatial resolution, specific cell 
type, or a function of the type of ALS model. 
Astrocytes use the enzyme glutamine synthetase (GS) to convert glutamate to 
glutamine as part of the glutamate/GABA-glutamine cycle (Norenberg and Martinez-
Hernandez, 1979; Bak et al., 2006) It is possible the constant levels of glutamate indicate 
SOD1-G93A astrocytes are reuptaking glutamate at higher rates and immediately 
converting it to maintain homeostasis. However, if glutamate was being taken in at higher 
rates it would require significant increases in GLT-1 and GluR to transport it into the cells. 
No such increases were found in this analysis. Rather, GLT-1 and GluR1 levels actually 
decreased compared to WT near end stage.   
There a few possible explanations for the decrease in GLT-1 and/or GluR1 levels.  
First, GLT-1 decreases could possibly be attributed to the difference in metabolic needs of 
astrocytes and neurons.  Since GLT-1 activity in astrocytes leads to an influx of Ca2+ 
through the energy powered Na+-Ca2+ exchanger (Bazargani and Attwell, 2016), 
metabolic impairment in astrocytes would also lead to decreased GLT-1 activity.  A second 
explanation for the decrease of GLT-1 and GluR1 over ALS disease progression could 
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simply be due to the lower number of living or fully functioning cells in later stages of 
ALS.  Finally, if there are potential cell-specific or spatially localized increases in 
excitation [spatial differences were not able to be examined in the present work], decreases 
in GLT-1 could suggest failed regulation or an inadequate compensatory response.   
Beyond glutamate-related findings, there were several other neuromodulatory 
findings revealed in the present study that provide further insight.  For example, GABA, 
an inhibitory neurotransmitter, is not upregulated over the course of ALS in mixed cell 
cultures.  If glutamate and other excitatory transmitters were in excess (either due to over-
production or do to impaired re-uptake), it would be expected that GABA follow a similar 
trend due to innate compensatory mechanisms to balance excitation and inhibition.   In the 
present study, neither GABA nor glutamate were significantly different in preclinical ALS 
compared to wild type.  Notably, aspartate, another excitatory neurotransmitter similar to 
glutamate, did show a slight increase in end stage preclinical ALS.  However, ChAT, which 
is used to make the neurotransmitter acetylcholine, showed no significant difference. 
In summary, there were no major changes in key neuromodulators that would point 
to very obvious glutamate-related excitotoxicity. Rather, the evidence presented here for 
mixed ALS cell cultures would suggest that direct neuromodulatory changes are subtle to 
modest, at least in SOD1 G93A ALS mixed cell cultures.  This would suggest that, if 
excitotoxicity is present, it could be due to the fact that ALS neurons and astrocytes have 
properties that make them simply more susceptible or sensitive to even small changes in 
neuromodulation.  Thus, even small or seemingly insignificant oscillatory increases or 
decreases in neuromodulators, which could easily be rectified with compensatory 
regulation in normal cells, could potentially wreak havoc in ALS cells.  In fact, as discussed 
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in more detail in Section 4.3, motoneurons are mathematically and functionally more 
susceptible to such instability (Mitchell and Lee, 2012, Irvin et. al., 2015).  Other recent 
work has also illustrated that motoneuron microcircuits are more prone to homeostatic 
dysregulation (Brownstone and Lancelin, 2017). Given the large variance in experimental 
data, small changes that were statistically insignificant may actually be physiologically 
significant to ALS cells.  If ALS cells are not able to sufficiently control their 
microenvironment, there could be spatial “pockets” or temporal phases of both 
hyperexcitability and hypoexcitability.  This could mean that both hyperexcitability and 
hypoexcitability could co-exist in ALS, which could explain the discrepancies seen in 
previous literature. 
4.2 Astrocyte GLT-1 as a potential post-onset ALS treatment target  
Due to the modest success of Riluzole, a drug used to treat ALS that is thought to 
increase glutamate reuptake, there has been significant focus on finding ways to increase 
the reuptake of glutamate by astrocytes (Do-Ha, 2017). Additionally, post-mortem studies 
of ALS tissue and mice have found reduced levels of EAAT2 and GLT-1, respectively 
(Rothstein et al., 1995, Pardo et al., 2006). It is believed that decreased GLT-1 levels are 
contributing to the accumulation of extracellular glutamate and increasing the levels could 
help prevent the hyperexcitability of the motoneurons. Few experiments have had any 
notable success, however, due to the complex interaction and timing of the 
pathophysiology (Li et al. 2015).  The present study found that GLT-1 levels only decrease 
significantly from post-onset to end-stage (Figure 1B). This finding suggests that 
increasing GLT-1 levels before ALS end-stage may increase glutamate reuptake, thereby 
prolonging survival or minimally prolonging muscle function after ALS onset.  
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If cell-specific or spatially localized excitation is present, extrinsically increasing 
GLT-1 levels before ALS end-stage may increase glutamate reuptake, thereby prolonging 
survival or minimally prolonging muscle function after ALS onset.  Recent analysis has 
illustrated the potential impact of treatments that can increase patient quality by preserving 
muscle function for as long as possible even if corresponding survival increases are not 
dramatic. For example, similar metadata analysis of oxidative stress treatments in high 
copy SOD1-G93A ALS mice prolong limb muscle function by 59.6% but only prolong 
survival by 11.2% (Bond et al., 2018) . 
4.3 Astrocyte GluR as a potential pre-onset ALS treatment target  
The influx of Ca2+ caused by the overstimulation of motoneurons leads to cell death 
as Ca2+ is involved in many apoptotic pathways. The permeability of glutamate receptors 
is determined by GluR subunits. Glutamate receptors with GluR1 subunits are highly 
permeable to Ca2+ and causes the mobilization of intracellular Ca2+ when activated 
(D’Antoni et al., 2011). GluR2 lacking glutamate receptors are highly permeable to Ca2+ 
(Grosskreutz, 2010). Studies have shown that a lack of GluR2 increased motoneuron 
degeneration (Van Damme et al., 2005) in mice and increasing GluR2 levels in 
motoneurons prolonged survival of mice (Tateno et al, 2004). While decreased GluR2 
levels were not observed in ALS mixed cultures in this study, there was a decrease in 
GluR1 levels at end-stage when compared to post-onset (Figure 1C), possibly from the 
high levels of cell death that have occurred by that point. Additionally, GluR1 is elevated 
from WT at post-onset, though this difference was not found to be significant, likely owing 
to small sample size. These findings suggest that reducing GluR1 levels in astrocytes at 
pre-onset, prior to their elevation post-onset, could reduce intracellular Ca2+ levels and 
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Ca2+ dysregulation effects. Due to the limited number of data points available for 
intracellular Ca2+ measured, the relationships of Ca2+ and the GluR subunits were unable 
to be examined.  
Of course, treatment at “pre-onset” in clinical terms would mean treatment in familial 
or genetic cases of ALS, referred to as FALS, where disease predisposition or the presence 
or pre-symptomatic ALS could be identified well before symptoms. Such a treatment is 
not realistic at this point because precise, reliable tests for explicit ALS identification [prior 
to symptom onset] are not yet available, even for FALS. The ability to identify more 
reliable biomarkers, genetic or otherwise, that predict future onset of ALS would open up 
the possibility of prophylactic treatment pre-onset. Such an approach would be similar to 
the familial amyloid- treatments being tested prophylactically in a known Colombian 
family where genetic tests can predict with certainty who will get a very specific form of 
familial Alzheimer’s Disease well before cognitive symptoms appear (Reardon, 2018).  
Early preclinical evidence illustrates that infamous amyloid- treatments, when used alone, 
may require prophylactic treatment to be successful (Huber et al., 2018). While many 
FALS markers have been identified, albeit SOD1, C9orf72, or the even more rare 
mutations like FUS/TLS, VAPB, etc. (Ajroud-Driss and Siddique, 2015), no such marker 
has yet been identified that definitively, with great sensitivity and specificity, can pre-
determine a future FALS onset. 
4.4 Elucidating etiology of Ca2+ increase in ALS 
Measuring intracellular calcium can be very complicated. Ca2+ transients are 
spatially localized within the astrocyte (Bazargani and Attwell, 2016). Due to 
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methodological constraints, the full intracellular Ca2+ store may not be found by simply 
looking at the soma, which complicates experimental Ca2+ examination in astrocytes at 
the present time.  Given the complications of local, spatial, and temporal Ca2+ 
experimental examination, it is difficult to determine what mechanism is most directly 
related to the increases in Ca2+ that have been previously identified in ALS (Irvin et al., 
2015). 
In healthy astrocytes, glutamate transporter activity leads to an increased entry of 
Na+ as GLT-1 couples glutamate and Na+ (Bazargani and Attwell, 2016). In addition to 
the Na+-K+ ATPase pump, the Na+-Ca2+ exchange provides a way for this Na+ to exit 
while Ca2+ enters. Therefore, an increase in glutamate uptake through GLT-1 activity can 
lead to increase in intracellular Ca2+. ALS astrocytes do not appear to increase glutamate 
uptake over disease progression and, consequently, do not increase intracellular Ca2+ 
concentrations. Neurons, however, can become increasingly more susceptible to glutamate 
excitotoxicity over time and, thus, see a rise in intracellular Ca2+. 
Interestingly, early pre-onset elevation of intracellular Ca2+ in SOD1-G93A mixed 
cell cultures occurs without a concurrent increase in intracellular glutamate. Thus, the 
mechanisms causing failed astrocytic Ca2+ regulation is not explicitly tied to glutamate. 
Exocytosis of GABA is, in part, dependent on the influx of Ca2+ through voltage-gated 
calcium channels (VGCCs) (Sitges and Chiu, 1995). However, we found no increase in 
GABA in ALS preclinical model mixed cell cultures.  Thus, unless there are localized 
changes in excitatory neurotransmitters that have not yet been experimentally measured, 
the increase in Ca2+ appears to not be directly tied to changes in excitatory 
neurotransmitter balance—at least not in preclinical ALS mixed cell cultures analyzed in 
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the present study.  Interestingly, a recent study showed that clinical patients with the 
C9ORF72 mutation had motoneurons that were more vulnerable Ca2+ permeable AMPA 
receptors (Selvaraj et. al., 2018). 
Ca2+ increases could come from a variety of mechanisms beyond direct or 
significant changes in neuromodulatory transmission. As proposed in prior work (Mitchell 
and Lee, 2012; Kim et al., 2015; Mitchell et al., 2015b; Hollinger et al., 2016), failed 
homeostasis in nearly ten different major pathways could explain how a variety of different 
perturbations that result in ALS and identified  homeostatic regulatory instability.  Ca2+ 
regulation is also greatly impacted by changes in energetic pathways (namely mitochondria 
and endoplasmic reticulum Ca2+ stores) and oxidative stress (Bond et. al., 2016), and to a 
lesser degree, by apoptotic signaling (Irvin et. al., 2015).   
Motoneurons are more prone to instability due to their long length (Mitchell and Lee, 
2012), which requires transport and signaling over very long distances in the axon. Any 
delays or offset in signaling within cells or even between cells, such as between neurons 
and astrocytes, could contribute to oscillatory instability.  The oscillations seen in CNS 
experimental data, and especially Ca2+, support the homeostatic instability theory (Irvin 
et al., 2015) of ALS.  Given the the very small margin of error for homeostatic regulation 
in motoneurons (Mitchell and Lee, 2012), localized examination of Ca2+ with sufficient 
spatio-temporal resolution in the future could provide key evidence for experimentally 
confirming the contributions, or lack thereof, of neuromodulatory regulation mechanisms 
in neurons and astrocytes. 
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4.5 Puzzling non-correlation between calcium-permeable GluR1 and TNF 
In general, TNF production and secretion is believed to be highly dependent upon 
calcium levels (Watanabe, 1996). One mechanism proposed for TNFα‐induced neuron 
death is through the rapid TNFα‐induced surface expression changes of AMPA‐type 
glutamate receptors, such as GluR1 (Ferguson et al., 2008). Dysregulation of glutamate 
receptor trafficking can alter neuronal calcium permeability and contribute to excitotoxic 
vulnerability (Olmos and Llado, 2014;Kia et al., 2018). 
Therefore, the lack of a statistically significant relationship between TNF and 
GluR1 levels in SOD1-G93A mixed cultures was unexpected (Figure 6). Moreover, the 
PCA (Figure 5A) showed TNF and GluR1 levels to be practically decoupled given TNF 
is almost orthogonal to GluR1 on the biplot (Figure 5A), which also indicates a lack of 
relationship.  
Of course, TNF has a complex relationship with many cellular processes.  It could 
be that the data variance identified and imparted by TNF in the PCA is more related to 
its other roles, including inflammation, synaptic function, and especially caspase-8 
initiated apoptosis (Kia et al., 2018). On a more detailed level, TNFα and NF‐ĸB have been 
shown to participate in oscillatory positive feedback loops wherein NF‐ĸB can regulate 
TNFα transcription.  This process plays a key role in regulating inflammatory responses 
across a variety of cell types, and has been found to be central in the FUS mutation of ALS 
(Pekalski et al., 2013) as well as other neurodegenerative diseases.  Another possible role 
of TNFα could be its relationship with glial derived neurotrophic factor, GDNF. Recent 
work has shown that TNFα contributes to rises in astrocytic GDNF that have a protective 
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effect on neuron damage (Brambilla et al., 2016); in fact, the TNFα –GDNF mechanism is 
currently being sought as a potential therapeutic target.  Most recently, astrocytes in the 
ALS FUS model were shown to induce motoneuron death directly via the release of TNFα 
(Kia et. al., 2018). 
Thus, while more research is necessary to examine the puzzling lack of relationship 
seen between TNFα and GluR1 levels, it appears both GluR1 and TNFα are each having 
an impact on ALS pathology, but the direct relationship between TNFα and GluR1 is 
simply not substantial in SOD1-G93A ALS mixed cell cultures. 
4.6 Aspartate increases near end-stage 
Aspartate is another excitatory neurotransmitter, similar to glutamate, that is found 
in the brain. In the present metadata analysis of preclinical ALS mixed cell cultures, the 
aspartate increase is not seen until end-stage. This supports the finding of normal or slightly 
decreased aspartate levels in cerebral spinal fluid serum of ALS patients with a mild disease 
course (Niebroj-Dobosz and Janik, 1999). In severely progressing patients, aspartate levels 
were increased, and GABA levels were normal or increased. When the imbalance of these 
amino acids favors the excitatory over the inhibitory, it appears to contribute to a more 
rapid decline in survival. 
4.7 Failed regulation could contribute to spatial spread of ALS 
An important characteristic of ALS is the spread of motoneuron degeneration and 
corresponding cell death. Recent research has found that transplanting familial ALS 
astrocytes into healthy mice causes ALS-like degeneration in non-specific healthy neurons 
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(Qian et al., 2017). The spread has been partially attributed to a prion-like mechanism 
(Grad et al., 2015). More research is needed to better understand the mechanistic etiology 
of the spread of ALS.  Nonetheless, one of the most prominent theories has been related to 
excitotoxic spillover.  For example, gliotransmitters, such as increased glutamate or 
decreased GABA, can propagate the rise of intracellular calcium levels in astrocytes and 
adjacent neurons. Glutamate can be released from astrocytes through Ca2+-activated 
bestrophin-1 anion channels. Changes in intracellular calcium levels in astrocytes can also 
affect the activity of membrane transporters, such as GluRs (Bazargani and Attwell, 2016). 
Yet, in the present metadata analysis in preclinical ALS mixed cell cultures, we did not see 
glaring evidence of severe excitotoxic spillover in preclinical ALS mixed cell cultures, as 
key excitatory (glutamate) and inhibitory transmitters (GABA) were not elevated.  
However, the identified decrease in inhibitory GLT-1 and increase of excitatory aspartate 
that occurs with disease progression does suggest there is at least a mild form of 
neuromodulatory regulation, or lack thereof, that is contributing to ALS etiology. 
Additionally, the presented analysis does illustrate potential evidence of upregulation, 
spillover or spread of other chemokines, especially TNF.  Dysregulated or delayed 
neuromodulator regulatory signaling between neurons and astrocytes should be further 
explored in future experimental work; evidence of dysregulation could be subtler than what 
is typically seen with primary excitotoxicity but could nonetheless help to explain the 
underlying “spread” mechanism(s) of ALS. 
4.8 Other non-inflammatory functions of astrocytes 
ALS-causing genes are also linked to lipid homeostasis, glucose homeostasis, 
mitochondrial formation, ATP production, and other metabolic functions (Ngo and Steyn, 
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2015). Extracellular concentrations of ATP in the CNS regulate activation and migration 
of immune and glial cells and increase in response to trauma and inflammation (Gandelman 
et al., 2010). In astrocytes, it can cause pro-inflammatory signaling which causes an 
increased production of nitric oxide and various chemokines (Gandelman et al., 2010). It 
has been found that G93A astrocytes degrade ATP at a faster rate than non-transgenic 
astrocytes and display ATP-dependent proliferation. It has also been shown that high 
extracellular concentrations of ATP can cause non-transgenic astrocytes to induce 
motoneuron death (Gandelman et al., 2010). Evidence shows that a complicated cycle of 
bioenergetic deficits may worsen disease progression over time (Ngo and Steyn, 2015). An 
analysis of extracellular ATP was not completed as part of this study due to lack of data 
meeting inclusion criteria. However, a similar analysis of ATP in the CNS shows 
deficiency throughout the SOD1-G93A ALS life span (Irvin et al., 2015). Like glutamate, 
the temporal trends of metabolic homeostasis need to be determined to identify the most 
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